97337 ⎘
Fusion polypeptide fusions for targeting to specific cell types, e.g. tissue specific targeting, targeting of a bacterial subspecies
ANTI-HER2 AFFIBODY AND SWITCHABLE CHIMERIC ANTIGEN RECEPTOR USING SAME AS SWITCH MOLECULE
#602CHIMERIC ANTIGEN RECEPTORS TARGETING GLYPICAN-2
#603CD123 TARGETED IMMUNOTHERAPIES
#604PLATFORM FOR ENHANCED TARGETED CELL DELIVERY
#605NOVEL PEPTIDES AND COMBINATION OF PEPTIDES FOR USE IN IMMUNOTHERAPY AGAINST LUNG CANCER, INCLUDING NSCLC AND OTHER CANCERS
#606NEF-CONTAINING T CELLS AND METHODS OF PRODUCING THEREOF
#607Codon-optimized nucleotide sequences encoding an AP-1 transcription factor
#608CELL THERAPY METHODS
#609MHC class I epitope delivering polypeptides
#610METHODS AND COMPOSITIONS FOR GENETICALLY MODIFYING LYMPHOCYTES TO EXPRESS POLYPEPTIDES COMPRISING THE INTRACELLULAR DOMAIN OF CD79A AND CD79B
#611GENETICALLY MODIFIED CELLS AND USES THEREOF
#612ENGINEERED T CELLS AND USES THEREFOR
#613CAR library and scFv manufacturing method
#614RECOMBINANT ANTIMICROBIAL MULTIDOMAIN POLYPEPTIDE, METHODS OF PRODUCING AND USES THEREOF
#615CAR FOR USE IN THE TREATMENT OF HVG DISEASE
#616IMMUNE CELL FUNCTION
#617CHIMERIC ANTIGEN RECEPTORS FOR TREATING MYELOID MALIGNANCIES
#618Targeted IL-12 treatments and methods to stimulate haNK and NK92mi cells
#619COMPOSITIONS FOR TREATMENT OF WET AGE-RELATED MACULAR DEGENERATION
#620Anti-podocalyxin antibodies and methods of using the same
#621GENETICALLY ENGINEERED T CELLS WITH PTPN2 KNOCKOUT HAVE IMPROVED FUNCTIONALITY AND ANTI-TUMOR ACTIVITY
#622Primary NK CAR Constructs And Methods
#623SINGLE CHAIN FUSIONCONSTRUCTS COMPRISING MULTIMERIC ANTIBODY FRAGMENTS FUSED TO COLLAGEN TRIMERIZATION DOMAINS
#624BISPECIFIC ANTIBODY CAR CELL IMMUNOTHERAPY
#625Construction of chimeric antigen receptor targeting CD20 antigen and activity identification of engineered T cells thereof
#626Fusion molecules and IL-15 variants
#627DE-IMMUNIZED, SHIGA TOXIN A SUBUNIT SCAFFOLDS AND CELL-TARGETING MOLECULES COMPRISING THE SAME
#628METHODS AND COMPOSITIONS FOR ADOPTIVE CELL THERAPY
#629Anti-VEGF protein compositions and methods for producing the same
#630De-immunized Shiga toxin a subunit effector polypeptides for applications in mammals
#631Compositions and Methods for Treating Elevated Secretory Activity
#632GENETICALLY MODIFIED NK CELLS AND USES THEREOF
#633Cell-targeted cytotoxic constructs
#634EPCAM BINDING PROTEINS AND METHODS OF USE
#635COVALENT ADAPTOR SYNNOTCH AND CHIMERIC ANTIGEN RECEPTORS (CARS) FOR PROGRAMMABLE ANTIGEN-TARGETING
#636CHIMERIC ANTIGEN RECEPTORS FOR DIRECT AND INDIRECT TARGETING OF FIBRONECTIN-POSITIVE TUMORS
#637FOXP3 TARGETING AGENT COMPOSITIONS AND METHODS OF USE FOR ADOPTIVE CELL THERAPY
#638COMPOSITION AND METHOD FOR ADOPTIVE IMMUNOTHERAPY
#639SYNTHETIC IMMUNE CELLS AND METHODS OF USE THEREOF
#640IMMUNOTHERAPIES
#641ANTIGEN BINDING MOLECULES COMPRISING A TNF FAMILY LIGAND TRIMER
#642ANTIBODIES BINDING TO GPRC5D
#643KNOCKDOWN OR KNOCKOUT OF ONE OR MORE OF TAP2, NLRC5, B2m, TRAC, RFX5, RFXAP and RFXANK TO MITIGATE T CELL RECOGNITION OF ALLOGENEIC CELL PRODUCTS
#644Anti-BCMA single domain antibodies and application thereof
#645IMMUNOTHERAPY TARGETING CELL SURFACE MARKER CD72 FOR THE TREATMENT OF B-CELL MALIGNANCIES
#646Engineered platelets for targeted delivery of a therapeutic agent
#647CHIMERIC ANTIGEN RECEPTOR WITH 4-IBB COSTIMULATORY DOMAIN
#648Chimeric antigen receptor dendritic cell (CAR-DC) for treatment of cancer
#649Adeno-Associated Virus Virions with Variant Capsid and Methods of Use Thereof
#650NOVEL IMMUNOCONJUGATES
#651ENGINEERED T-CELLS CO-EXPRESSING AN ANTI-BCMA CAR AND AN ANTI-ECTOENZYME ANTIBODY AND THEIR USE IN THE TREATMENT OF CANCER
#652GHR-106 CHIMERIC ANTIGEN RECEPTOR CONSTRUCT AND METHODS OF MAKING AND USING SAME
#653Novel Selective ACKR3 Modulators and Uses Thereof
#654ARTIFICIAL RECEPTORS, RECOMBINANT CELLS COMPRISING THEREOF, METHODS FOR THEIR PREPARATION, AND METHOD OF USING THEREOF
#655HUMANIZED ANTIBODIES TO MUCIN-16 AND METHODS OF USE THEREOF
#656Anti-VEGF protein compositions and methods for producing the same
#657De novo design of potent and selective interleukin mimetics
#658EXOSOME COMPRISING STABILIZED RNA THERAPEUTICS
#659Chimeric antigen receptor dendritic cell (CAR-DC) for treatment of cancer
#660Methods and compositions for modulating CAR-T activity
#661Anti-VEGF protein compositions and methods for producing the same
#662Anti-VEGF protein compositions and methods for producing the same
#663ENGINEERED GLOBULAR ENDOLYSIN, A HIGHLY POTENT ANTIBACTERIAL ENZYME FOR MULTIDRUG RESISTANT GRAM-NEGATIVE BACTERIA
#664Methods for efficient delivery of therapeutic molecules in vitro and in vivo
#665Coordinating gene expression using RNA destabilizing elements
#666CD79B CHIMERIC ANTIGEN RECEPTORS
#667MOUSE MODEL FOR ASSESSING TOXICITIES ASSOCIATED WITH IMMUNOTHERAPIES
#668Method for Generation of Genetically Modified T Cells
#669Humanized BCMA antibody and BCMA-CAR-T cells
#670INTERFERON ALPHA 2B VARIANTS
#671Separation moieties and methods of use thereof
#672AAV CAPSID CHIMERIC ANTIGEN RECEPTORS AND USES THEREOF
#673TARGETED DELIVERY OF THE ABRIN-A A-CHAIN TO CANCER CELLS
#674Method for detecting flavivirus-specific antibodies utilizing flaviviral NS1 polypeptides comprising the wing domain
#675BONE-SPECIFIC COMPLEX COMPRISING BONE CELL TRANSFORMATION RECOMBINANT PROTEIN AND BONE-TARGETING MOLECULE
#676TAILORED HYPOIMMUNE NANOVESICULAR DELIVERY SYSTEMS FOR CANCER TUMORS
#677CAR T-CELLS TARGETING BCMA AND USES THEREOF
#678DHFR tunable protein regulation
#679MÜLLERIAN INHIBITING SUBSTANCE TYPE 2 RECEPTOR (MISIIR)-SPECIFIC CAR T CELLS FOR THE TREATMENT OF OVARIAN CANCER AND OTHER GYNECOLOGIC MALIGNANCIES
#680ANTI-GPIIB/IIIA ANTIBODIES OR USES THEREOF
#681NOVEL PEPTIDES AND COMBINATION OF PEPTIDES FOR USE IN IMMUNOTHERAPY AGAINST LUNG CANCER, INCLUDING NSCLC AND OTHER CANCERS
#682GENOMIC SAFE HARBORS FOR TRANSGENE INTEGRATION
#683EXTRACELLULAR VESICLES DERIVED FROM ACTIVATED CAR-T CELLS
#684ANTIBODIES AGAINST PROGRAMMED CELL DEATH PROTEIN 1 (PD1) AND USES THEREOF
#685CHIMERIC ANTIGEN RECEPTORS TARGETING CD-19
#686Antibody or chimeric antigen receptor which targets Claudin 18.2
#687Synthetic immune receptors and methods of use thereof
#688ICAM-1 targeted fusion enzymes
#689CHIMERIC ANTIGEN RECEPTOR DENDRITIC CELL (CAR-DC) FOR TREATMENT OF CANCER
#690COMBINATORIAL CAR T CELL AND HEMATOPOEITIC STEM CELL GENETIC ENGINEERING FOR SPECIFIC IMMUNOTHERAPY OF MYELOID LEUKEMIAS
#691MANUFACTURING ANTI-BCMA CAR T CELLS
#692Salvage chimeric antigen receptor systems
#693PATHOGEN BINDING METHODS AND COMPOSITIONS
#694Compositions and methods for internalizing enzymes
#695HYPOXIA-RESPONSIVE CHIMERIC ANTIGEN RECEPTORS
#696NOVEL PEPTIDES AND COMBINATION OF PEPTIDES FOR USE IN IMMUNOTHERAPY AGAINST LUNG CANCER, INCLUDING NSCLC AND OTHER CANCERS
#697Methods and composition for a binding molecule targeting cancer cells expressing SSX2 peptide 41-49 in HLA-A*0201 context
#698Genetically engineered dual-targeting chimeric antigen receptor and use thereof
#699CELL SURFACE COUPLING OF NANOPARTICLES
#700GENETICALLY MODIFIED IMMUNE CELL, PREPARATION METHOD THEREFOR, AND APPLICATION
#701METHODS AND COMPOSITIONS FOR IMPROVED PRODUCTION OF AN ANTIGEN FOR USE IN AN S. AUREUS VACCINE
#702MUTATED ADENO-ASSOCIATED VIRUS CAPSID PROTEINS, AAV PARTICLE COMPRISING THE SAME AND LIVER DIRECTED AAV VECTOR GENE THERAPY
#703NOVEL PEPTIDES AND COMBINATION OF PEPTIDES FOR USE IN IMMUNOTHERAPY AGAINST LUNG CANCER, INCLUDING NSCLC AND OTHER CANCERS
#704NOVEL PEPTIDES AND COMBINATION OF PEPTIDES FOR USE IN IMMUNOTHERAPY AGAINST LUNG CANCER, INCLUDING NSCLC AND OTHER CANCERS
#705CELLS EXPRESSING A RECOMBINANT RECEPTOR FROM A MODIFIED TGFBR2 LOCUS, RELATED POLYNUCLEOTIDES AND METHODS
#706Genetically Engineered Cells and Uses Thereof
#707CD8 BINDING AGENTS
#708TWO CHIMERIC ANTIGEN RECEPTORS SPECIFICALLY BINDING CD19 AND IGKAPPA
#709Novel Complex Comprising A Cell Penetrating Peptide, A Cargo And A TLR Peptide Agonist For Treatment Of Glioblastoma
#710Chimeric antigen receptors (CARS) that bind osteosarcoma and their use in medicine
#711TARGETED DELIVERY OF IMMUNE-MODULATING VHH AND VHH-FUSION PROTEIN
#712CHIMERIC ANTIGEN RECEPTOR DENDRITIC CELL (CAR-DC) FOR TREATMENT OF CANCER
#713CHIMERIC ANTIGEN RECEPTOR DENDRITIC CELL (CAR-DC) FOR TREATMENT OF CANCER
#714CD40L COMPOSITIONS AND METHODS FOR TUNABLE REGULATION
#715Tagged chimeric effector molecules and receptors thereof
#716T CELL RECEPTORS AND METHODS OF USE THEREOF
#717ANTIBODY VARIANTS WITH PH-DEPENDENT ANTIGEN BINDING FOR SELECTIVE TARGETING OF SOLID TUMORS
#718HUMANIZED ANTI-FOLATE RECEPTOR 1 CHIMERIC ANTIGEN RECEPTORS AND USES THEREOF
#719Anti-VEGF protein compositions and methods for producing the same
#720Method of treating skin tissue damage by topically administering a bi-specific protein comprising a human insulin-like growth factor variant and a human annexin A5 variant
#721FLT3-SPECIFIC CHIMERIC ANTIGEN RECEPTORS AND METHODS OF USING THE SAME
#722MUC16 specific chimeric antigen receptors and uses thereof
#723MUC16 specific chimeric antigen receptors and uses thereof
#724CHIMERIC ANTIGEN RECEPTORS TARGETING CD-19
#725T CELL RECEPTORS AND METHODS OF USE THEREOF
#726GENETICALLY-MODIFIED CELLS COMPRISING A MODIFIED HUMAN T CELL RECEPTOR ALPHA CONSTANT REGION GENE
#727CHIMERIC ANTIGEN RECEPTOR AND USE THEREOF
#728GENETICALLY-MODIFIED CELLS COMPRISING A MODIFIED HUMAN T CELL RECEPTOR ALPHA CONSTANT REGION GENE
#729Compositions for treating pathological calcification conditions, and methods using same
#730Restimulation of cryopreserved tumor infiltrating lymphocytes
#731Notch receptors with hinge domain
#732FUSION PROTEIN FOR USE IN THE TREATMENT OF HVG DISEASE
#733IMMUNE EFFECTOR CELL AND USE THEREOF
#734CHIMERIC ANTIGEN RECEPTORS TARGETING BCMA AND METHODS OF USE THEREOF
#735Antigen binding regions against fibronectin type III domains and methods of using the same
#736Methods for producing aflibercept in chemically defined media having reduced aflibercept variants
#737Compositions and methods for regulating production of a fusion protein and ribonucleic acid
#738Compositions for preventing or treating viral and other microbial infections
#739MODULATION OF DENDRITIC CELL LINEAGES
#740CHIMERIC ANTIGEN RECEPTOR DENDRITIC CELL (CAR-DC) FOR TREATMENT OF CANCER
#741Immune cell compositions and methods of use
#742BIFUNCTIONAL MOLECULES WITH IL-7 ACTIVITY
#743MUL TISPECIFIC PROCHEMOKINE THERAPEUTIC PROTEINS (PARK) AND METHOD OF MAKING AND USING THEREOF
#744CHIMERIC ANTIGEN RECEPTORS
#745Interleukin-15 (IL-15) fusion proteins and uses thereof
#746REDUCING CD33 EXPRESSION TO SELECTIVELY PROTECT THERAPEUTIC CELLS
#747Monoclonal antibody targeting a unique sialoglycosylated cancer-associated epitope of CD43
#748Anti-VEGF protein compositions and methods for producing the same
#749Chimeric engulfment receptor molecules
#750METHODS AND COMPOSITIONS RELATING TO IMPROVED FORMS OF TARGETED ERYTHROPOIETIN
#751PEPTIDE TAGS FOR LIGAND INDUCED DEGRADATION OF FUSION PROTEINS
#752Selective recovery
#753Restimulation of cryopreserved tumor infiltrating lymphocytes
#754Modified Cell Expansion and Uses Thereof
#755REMOVAL OF TARGET CELLS BY CIRCULATING VIRUS-SPECIFIC CYTOTOXIC T-CELLS USING MHC CLASS I COMPRISING COMPLEXES
#756ANTI-GLYCOPROTEIN IIb/IIIa ANTIBODIES
#757HETERODIMERIC FUSION PROTEIN
#758Anti-CD55 Antibodies and Related Compositions and Methods
#759Restimulation of cryopreserved tumor infiltrating lymphocytes
#760Restimulation of cryopreserved tumor infiltrating lymphocytes
#761COMBINATION THERAPIES OF EGFRVIII CHIMERIC ANTIGEN RECEPTORS AND PD-1 INHIBITORS
#762Claudin18.2 binding moieties and uses thereof
#763Use of CD2/5/7 knock-out anti-CD2/5/7 chimeric antigen receptor T cells against T cell lymphomas and leukemias
#764COMPOSITIONS AND METHODS FOR TREATING AUTOIMMUNE DISEASES
#765Chimeric antigen receptor effector cell switches with humanized targeting moieties and/or optimized chimeric antigen receptor interacting domains and uses thereof
#766PEPTIDE IMMUNOGENS TARGETING CALCITONIN GENE-RELATED PEPTIDE (CGRP) AND FORMULATIONS THEREOF FOR PREVENTION AND TREATMENT OF MIGRAINE
#767GENE MODIFIED IMMUNE EFFECTOR CELLS AND ENGINEERED CELLS FOR EXPANSION OF IMMUNE EFFECTOR CELLS
#768Expression of novel cell tags
#769Anti-idiotypic antibodies against anti-KLK2 antibodies
#770Cross species single domain antibodies targeting mesothelin for treating solid tumors
#771Treatment of cancer using humanized anti-BCMA chimeric antigen receptor
#772T cell modification and use thereof
#773Drug regulated transgene expression
#774ANTI-TCR ANTIBODY MOLECULES AND USES THEREOF
#775Innocuous, structured scaffolds for structure-based amyloid disease vaccines and antigens
#776Panel comprising MHC multimers
#777PSCA CAR-T CELLS
#778Lym-1 and Lym-2 antibody compositions and improved car constructs
#779Compositions and Methods for Generating a Persisting Population of T Cells Useful for the Treatment of Cancer
#780D-domain containing polypeptides and uses thereof
#781De novo design of potent and selective interleukin mimetics
#782Membrane bound IL12 compositions and methods for tunable regulation
#783Peptides and combination of peptides and scaffolds for use in immunotherapy against renal cell carcinoma (RCC) and other cancers
#784Dendritic cell ASGPR targeting immunotherapeutics for multiple sclerosis
#785PHAGE DERIVED ANTIMICROBIAL ACTIVITIES
#786Adenovirus vectors and methods for using adenovirus vectors
#787ANTIBODIES AGAINST THE MUC1-C/EXTRACELLULAR DOMAIN (MUC1-C/ECD)
#788Antibodies specific to CD44
#789Engineered immune cells targeting BCMA and their uses thereof
#790CR3022 chimeric antigen receptors and methods of use
#791Anti-VEGF protein compositions and methods for producing the same
#792METHODS FOR THE SIMULTANEOUS EXPANSION OF MULTIPLE IMMUNE CELL TYPES, RELATED COMPOSITIONS AND USES OF SAME IN CANCER IMMUNOTHERAPY
#793ANTIBODIES SPECIFIC TO MUC18
#794Anti-CD38 antibodies and methods of use
#795BAFF-R antibodies and uses thereof
#796FUSION PROTEIN OF SINGLE DOMAIN ANTIBODY AND PROCOAGULANT
#797A GROUP OF CHIMERIC ANTIGEN RECEPTORS (CARS)
#798REGULATABLE CELL SURFACE RECEPTORS AND RELATED COMPOSITIONS AND METHODS
#799Engineered platelets for targeted delivery of a therapeutic agent
#800Complex comprising a cell penetrating peptide, a cargo and a TLR peptide agonist
#801Peptides and combination of peptides and scaffolds for use in immunotherapy against renal cell carcinoma (RCC) and other cancers
#802Peptides and combination of peptides for use in immunotherapy against lung cancer, including NSCLC and other cancers
#803Anti-VEGF protein compositions and methods for producing the same
#804Methods for producing aflibercept in chemically defined media having reduced aflibercept variants
#805Complex comprising a cell penetrating peptide, a cargo and a TLR peptide agonist for treatment of colorectal cancer
#806CHIMERIC ANTIGEN RECEPTOR-MODIFIED NK-92 CELLS TARGETING EGFR SUPER-FAMILY RECEPTORS
#807BISPECIFIC ANTIGEN BINDING MOLECULES COMPRISING LIPOCALIN MUTEINS
#808Dimerizing agent regulated immunoreceptor complexes
#809Nucleic acid constructs for co-expression of chimeric antigen receptor and transcription factor, cells containing and therapeutic use thereof
#810Fusion proteins with extended serum half life
#811Articles and methods directed to personalized therapy of cancer
#812MULTICISTRONIC VECTOR FOR SURFACE ENGINEERING LENTIVIRAL PARTICLES
#813Repair of UV-induced DNA lesions
#814Humanized BCMA antibody and BCMA-CAR-T cells
#815Bispecific polypeptides for engagement of CAR expressing immune cells with antigen presenting cells and uses thereof
#816MULTIMERIC T-CELL MODULATORY POLYPEPTIDES AND METHODS OF USE THEREOF
#817EXPOSED COLLAGEN-TARGETED FUSION CYTOKINE FOR IMMUNE MODULATION IN INVASIVE CANCERS AND LESIONS OF INFECTIONS
#818BAFF-R targeted chimeric antigen receptor-modified T-cells and uses thereof
#819Anti-VEGF protein compositions and methods for producing the same
#820Anti-VEGF protein compositions and methods for producing the same
#821Anti-VEGF protein compositions and methods for producing the same
#822Bi-specific therapeutic proteins, in vivo methods of use thereof and encoding nucleic acids thereof
#823Immunosuppressive antigen-specific chimeric antigen receptor Treg cells for prevention and/or treatment of autoimmune and alloimmune disorders
#824Restimulation of cryopreserved tumor infiltrating lymphocytes
#825METHODS OF DOSING ENGINEERED T CELLS FOR THE TREATMENT OF B CELL MALIGNANCIES
#826COMPOUND AND METHOD FOR TREATING MYOTONIC DYSTROPHY
#827Constructs for chimeric antigen receptors
#828FIBRONECTIN BINDING DOMAIN CHIMERIC ANTIGEN RECEPTORS AND METHODS OF USE THEREOF
#829Modified meningococcal fHbp polypeptides
#830Restimulation of cryopreserved tumor infiltrating lymphocytes
#831Restimulation of cryopreserved tumor infiltrating lymphocytes
#832Restimulation of cryopreserved tumor infiltrating lymphocytes
#833Restimulation of cryopreserved tumor infiltrating lymphocytes
#834Modified Cell Expressing Therapeutic Agent and Uses thereof
#835Method of increasing tumor killing activity of macrophages or monocytes comprising chimeric antigen receptor
#836NOVEL CONSTRUCTS FOR CHIMERIC ANTIGEN RECEPTORS
#837CHIMERIC ADAPTOR AND KINASE SIGNALING PROTEINS AND THEIR USE IN IMMUNOTHERAPY
#838TARGETED MUTANT INTERFERON-GAMMA AND USES THEREOF
#839D-domain containing polypeptides and uses thereof
#840Anti-cancer fusion polypeptide capable of binding both CD137 and glypican-3 (GPC3)
#841Fusion-proteins based on human ferritin and protease-cleavable peptides and their use as chemotherapeutics carriers
#842D-domain containing polypeptides and uses thereof
#843Restimulation of cryopreserved tumor infiltrating lymphocytes
#844T CELLS FROM LYMPHATIC FLUID FOR DIAGNOSTIC AND THERAPEUTIC USE
#845TWO-GENE VECTORS FOR GENERATING CAR-T CELLS AND USES THEREOF
#846Anti-B7-H3 monoclonal antibody and use thereof in cell therapy
#847CD6 targeted chimeric antigen receptors for treatment of certain autoimmune disorders
#848THERAPEUTIC COMPOUNDS AND METHODS
#849MULTISPECIFIC PROTEINS
#850Peptides and combination of peptides and scaffolds for use in immunotherapy against renal cell carcinoma (RCC) and other cancers
#851Personalized immunotherapy against several neuronal and brain tumors
#852Coordinating gene expression using RNA destabilizing elements
#853METHODS FOR TREATMENT USING CHIMERIC ANTIGEN RECEPTORS SPECIFIC FOR B-CELL MATURATION ANTIGEN
#854ANTI-CD33 AND NKG2D LIGAND CHIMERAS FOR TREATMENT OF MYELOID MALIGNANCIES
#855Anti-epidermal growth factor receptor variant III chimeric antigen receptors and use of same for the treatment of cancer
#856Chimeric antigen receptor specific for interleukin-23 receptor
#857Chimeric antigen receptors with mutated CD28 phosphorylation sites
#858Immunocytes expressing a chimeric antigen receptor binding to cancer cells and TNF-related apoptosis-inducing ligand (trail)
#859Anti-VEGF protein compositions and methods for producing the same
#860IL2 AND TNF MUTANT IMMUNOCONJUGATES
#861Personalized immunotherapy against several neuronal and brain tumors
#862GENETICALLY ENGINEERED CAR T CELLS THAT SECRET INTERLEUKIN-12 AND THERAPEUTIC USES THEREOF
#863Construction of chimeric antigen receptor targeting CD20 antigen and activity identification of engineered T cells thereof
#864MULTI-SPECIFIC BINDING MOLECULES TARGETING ABERRANT CELLS
#865CHIMERIC ANTIGEN WITH ENHANCED MULTI-IMMUNE FUNCTION THROUGH SPECIFIC BINDING TO TARGET CELL, AND USE THEREOF
#866Masked chimeric antigen receptor specific to tyrosine-protein kinase like 7 (PTK7) and immune cells expressing such
#867Epcam antibody and Epcam-CAR-T cells
#868Reducing immune inhibition induced by SIGLEC-15
#869Fc-epsilon car
#870METHODS OF USING CHIMERIC ANTIGEN RECEPTORS TARGETING B-CELL MATURATION ANTIGEN AND USES THEREOF
#871Methods for making novel antigen binding domains
#872METHODS FOR IDENTIFYING CHIMERIC ANTIGEN RECEPTOR-TARGETING LIGANDS AND USES THEREOF
#873CHIMERIC RECEPTOR POLYPEPTIDES IN COMBINATION WITH TRANS METABOLISM MOLECULES MODULATING INTRACELLULAR LACTATE CONCENTRATIONS AND THERAPEUTIC USES THEREOF
#874Activatable IL2 composition and methods of use
#875Interleukin-2 polypeptides and fusion proteins thereof, and their pharmaceutical compositions and therapeutic applications
#876CHIMERIC ANTIGEN RECEPTORS (CARs) COMPOSITIONS AND METHODS OF USE THEREOF
#877ENGINEERED REGULATORY T CELL
#878ARTICLES AND METHODS DIRECTED TO PERSONALIZED THERAPY OF CANCER
#879TREATMENT FOR BK POLYOMAVIRUS INFECTION
#880Expression of novel cell tags
#881CHIMERIC ANTIGEN RECEPTORS SPECIFIC FOR B-CELL MATURATION ANTIGEN AND ENCODING POLYNUCLEOTIDES
#882CLL1-TARGETING ANTIBODY AND APPLICATION THEREOF
#883Methods and compositions comprising B7H3 chimeric antigen receptors
#884BISPECIFIC HER2 AND CD3 BINDING MOLECULES
#885Heterologous targeting peptide grafted AAVs
#886IL-2 variants with reduced binding to IL-2 receptor alpha and uses thereof
#887METHODS AND COMPOSITIONS FOR STIMULATION OF CHIMERIC ANTIGEN RECEPTOR T CELLS WITH HAPTEN LABELLED CELLS
#888Chimeric antigen receptor (CAR) that targets chemokine receptor CCR4 and its use
#889Antibodies to MUC16 and methods of use thereof
#890GD2-based chimeric antigen receptor and application thereof
#891Chimeric antigen receptor
#892EGFR-DIRECTED CAR THERAPY FOR GLIOBLASTOMA
#893Immunogenic composition against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)
#894Fusion proteins comprising an anti-CD40 antibody and cancer antigens
#895TAG72 targeted chimeric antigen receptor modified T cells for treatment of TAG72-positive tumors
#896Anti-EGFR1-PD1 targeted/immunomodulatory fusion protein
#897NPP1 FUSION PROTEINS
#898METHOD FOR PRODUCING CD3-POSITIVE CELL
#899METHODS FOR EXPANDING ANTIGEN-SPECIFIC CAR-T CELLS, COMPOSITIONS AND USES RELATED THERETO
#900COMPOSITIONS AND METHODS FOR IMMUNOTHERAPY TARGETING FLT3, PD-1, AND/OR PD-L1